怎么看待世卫组织会议报告中表示「中医药能有效治疗新冠」？ 第1页

骗术，往往不需要说假话，只要隐瞒部分真像就可以了。

题目中提到的的会议报告，在这里能下载^[1]：

WHO Expert Meeting on Evaluation of Traditional Chinese Medicine in the Treatment of COVID-19

其中前14页是会议记录，包括致辞、中国专家的三个报告和讨论。后面是总结和建议。

讨论结果：

The experts agreed that the studies presented had applied appropriate and rigorous methodology given the context in which they were being conducted.Although the trials involved different settings, the data suggested that TCM was both safe and beneficial when combined with conventional antiviral medicine. It was agreed that there are promising data on the benefits of TCM in reducing the disease exacerbation rate for mild and moderate cases of COVID-19. However, evidence on the benefit of TCM injection for severe cases is limited and further evaluation is critically needed.

结果表明中医在和常规抗病毒药物相结合使用时是安全和有效的。

大家同意中医在降低轻中度病例病情加重率方面是有益的。

然而，中药注射剂对重症病例有益的证据有限并且迫切需要进一步的评估。

这和题目所谓的“中医药能有效治疗新冠”不符

对成员国给出的建议：

The Expert Meeting recommended to Member States:

• to consider the potential use of TCM for the management of COVID-19 in the context of their health-care systems and regulatory frameworks;

• to share experiences and lessons, particularly those actively acquired through this organized research programme in TCM and clinical experience from China;

• to collaborate actively in clinical and mechanistic research to further evaluate and elucidate the clinical benefits and safety of TCM in the management of COVID-19;

• to collaborate in developing consistent approaches, where practicable, and to improve health-care systems for the management of the current pandemic and preparedness for future pandemics.

另一方面，WHO对Covid 19的Guildline在这里可以看到，Therapeutics and COVID-19^[2]

包括15项建议，其中不包括中医，也没有将中医列在正在考虑的COVID-19 疗法：

The WHO Therapeutics and COVID-19: living guideline currently includes a:

• ** NEW ** conditional recommendation for use of Molnupiravir for patients with non-severe COVID-19, conditional for those at highest risk of hospitalization (excluding pregnant or breastfeeding women, and children) (published 03 March 2022);
• ** UPDATED** conditional recommendation to use a combination of neutralizing monoclonal antibodies (casirivimab and imdevimab) (published 03 March 2022);
  
• ** UPDATED** conditional recommendation against remdesivir in hospitalized patients with COVID-19 (published 03 March 2022);
• strong recommendation for the use of baricitinib as an alternative to interleukin-6 (IL-6) receptor blockers, in combination with corticosteroids, in patients with severe or critical COVID-19 (published 14 January 2022);
• conditional recommendation against the use of ruxolitinib and tofacitinib for patients with severe or critical COVID-19 (published 14 January 2022);
• conditional recommendation for the use of sotrovimab in patients with non-severe COVID-19, conditional for those at highest risk of hospitalization (published 14 January 2022);
• strong recommendation against convalescent plasma in patients with non-severe COVID-19 (published 7 December 2021);
• recommendation not to use convalescent plasma in patients with severe or critical COVID-19 except in the context of a clinical trial (published 7 December 2021);
• conditional recommendation to use a combination of neutralizing monoclonal antibodies (casirivimab and imdevimab) in non-severe COVID-19 patients at the highest risk of severe disease (published 24 September 2021);
• conditional recommendation to use a combination of neutralizing monoclonal antibodies (casirivimab and imdevimab) in severe and critically ill COVID-19 patients with seronegative status (published 24 September 2021);
• strong recommendation to use IL-6 receptor blockers (tocilizumab or sarilumab) in patients with severe or critical COVID-19 (published 6 July 2021);
• recommendation not to use ivermectin in patients with COVID-19 except in the context of a clinical trial (published 31 March 2021);
• strong recommendation against hydroxychloroquine in patients with COVID-19 of any severity (published 17 December 2020);
• strong recommendation against lopinavir/ritonavir in patients with COVID-19 of any severity (published 17 December 2020);
• conditional recommendation against remdesivir in hospitalized patients with COVID-19 (published 20 November 2020);
• strong recommendation to use systemic corticosteroids in patients with severe and critical COVID-19 (published 2 September 2020); and
• conditional recommendation against systemic corticosteroids in patients with non-severe COVID-19 (published 2 September 2020).

Other COVID-19 therapeutics that are currently under consideration by WHO include molnupiravir, fluvoxamine, nirmatrelvir/ritonavir, colchicine and anticoagulants. This guideline will be updated if/when sufficient new evidence warrants this.

会议结论是consider the potential use of TCM，最多在下一版的guildline把中药放在最下面。

比如这样：Other COVID-19 therapeutics that are currently under consideration by WHO include TCM。This guideline will be updated if/when sufficient new evidence warrants this.

值得庆祝的是WHO并没有对TCM做出strong recommendation against或者conditional recommendation against的结论，比川大总统推荐的hydroxychloroquine和lopinavir/ritonavir被列为strong recommendation against要好太多了，我们又赢辣！

参考

1. ^ https://www.who.int/publications/m/item/who-expert-meeting-on-evaluation-of-traditional-chinese-medicine-in-the-treatment-of-covid-19
2. ^ https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2